Recombinant human gamma-interferon in primary hepatocellular carcinoma

Alastair Forbes, Philip J. Johnson, Roger Williams

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)


A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.
Original languageEnglish
Pages (from-to)826-829
Number of pages4
JournalJournal of the Royal Society of Medicine
Issue number10
Publication statusPublished - Oct 1985


  • Adult
  • Carcinoma, Hepatocellular
  • Drug Evaluation
  • Female
  • Humans
  • Interferon-gamma
  • Liver Neoplasms
  • Male
  • Middle Aged
  • Time Factors
  • alpha-Fetoproteins

Cite this